Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | IKZF3 |
| Gene Name: | IKZF3 |
| Protein Full Name: | Zinc finger protein Aiolos |
| Alias: | AIOL; Aiolos; IKAROS family zinc finger 3; Zinc finger protein Aiolos; ZNFN1A3 |
| Mass (Da): | 58023 |
| Number AA: | 509 |
| UniProt ID: | Q9UKT9 |
| Locus ID: | 22806 |
| COSMIC ID: | IKZF3 |
| Gene location on chromosome: | 17q21 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 20819 |
| Percent of cancer specimens with mutations: | 0.67 |
| Deregulated in translocations: | Breast Cancer, fusion partner is VAPB. |
| Normal role description: | IKZF3 is a hematopoeitic specific transcription factor which has a role in regulating B-cell development. IKZF3 has a role in the control of Bcl2 expression caused by interleukin receptor signalling to regulate apoptosis. In the absence of mitogen stimulation IKZF3 is localized to the cytoplasm which results in a decrease in Bcl2 expression and activation of apoptosis. IKZF3 has also been found to interact with other transcription factors including H-Ras, FOXP3 as well as histone deacetylases, HDAC1, MTA2 and SIN3A to regulate gene expression. The exact role of IKZFG3 in cancer development is still relatively unknown although its role in promoting apoptosis may classify it as a tumour suppressor protein in B-cells. Silencing events of the IKZF3 locus by DNA methylation has been observed in some cell lines. |